Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.
Prostate cancer (CaP) will be diagnosed in approximately 181,000 American men in 2016. Despite the high number of deaths from CaP in the United States, the disease has a protracted natural history and many men diagnosed with CaP will not die of the disease regardless of treatment. Unfortunately, identification of men with truly indolent/ nonaggressive CaP is challenging; limitations of conventional diagnostic modalities diminish the ability of physicians to accurately stage every case of CaP based on biopsy results alone. The resulting uncertainty in prognosis may prompt men with low-risk CaP to proceed to morbid and expensive treatments for an unclear survival benefit. Incorporation of the Genomic Prostate Score (GPS) as part of the decision algorithm for patients with National Comprehensive Cancer Network very low-risk and low-risk cancer led to a substantial increase in uptake of active surveillance and substantial cost savings. GPS provides physicians and patients with an additional tool in assessing personalized risk and helps guide individual decision making.
Associated Medical Professionals of NY, PLLC Syracuse, NY.
David
D
Albala
Genomic Health, Inc. Redwood City, CA.
Michael J
MJ
Kemeter
Genomic Health, Inc. Redwood City, CA.
Phillip G
PG
Febbo
Genomic Health, Inc. Redwood City, CA.
Ruixiao
R
Lu
Excellus BlueCross BlueShield Rochester, NY.
Vincy
V
John
Associated Medical Professionals of NY, PLLC Syracuse, NY.
Dylan
D
Stoy
Genomic Health, Inc. Redwood City, CA.
Bela
B
Denes
Excellus BlueCross BlueShield Rochester, NY.
Marybeth
M
McCall
Genomic Health, Inc. Redwood City, CA.
Alan W
AW
Shindel
Excellus BlueCross BlueShield Rochester, NY.
Frank
F
Dubeck
Clinical utility; Genomic testing; Health economics; Oncotype DX® GPS; Prostate cancer